Multimedia
View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Anti-inflammatory agents and immunomodulators are key components to treating patients who are severely or critically ill due to a COVID-19 infection.
In this episode, Vikramjit Mukherjee, MD, discusses the role and timing of these treatment options, including:
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Assistant Professor of Medicine
Division of Pulmonary, Critical Care, & Sleep Medicine
New York University School of Medicine
Director, Medical Intensive Care Unit
Bellevue Hospital
New York, New York
This program has been made available online.
Prof. Sharon R. Lewin: expert insights on remdesivir for nonhospitalized adult and pediatric patients with COVID-19, from Clinical Care Options (CCO)
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Released: June 7, 2022
Prof. Sharon R. Lewin discusses ivermectin and the evolution of monoclonal antibody treatments during omicron, from Clinical Care Options (CCO)
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Released: June 7, 2022
Megan Coffee, MD, PhD, discusses the newest data on SARS-CoV-2 diagnostics from CROI 2022 and elsewhere, from Clinical Care Options (CCO)
Megan Coffee, MD, PhD (DPhil)
Released: June 2, 2022
Frequently asked questions and answers: evolving data on COVID-19 epidemiology, prevention, and treatment, from Clinical Care Options (CCO)
Arthur Kim, MD
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Renslow Sherer, MD
Released: June 1, 2022
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.